RONALDO MAMARIL: Open Payments
NPI 1013301266 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 36 payments from 13 companies in 2025. Trend: 2023 $170 · 2024 $730 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 10 | $253 |
| ABBVIE INC. | 9 | $159 |
| Ardelyx, Inc. | 3 | $83 |
| GENZYME CORPORATION | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| PFIZER INC. | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Novo Nordisk Inc | 1 | $21 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $20 |
Products named: REZDIFFRA, DUPIXENT, IBSRELA, RINVOQ, CREON, XELJANZ, LINZESS, SKYRIZI.
Industry payments across NC — which companies pay providers there.
